Literature DB >> 2961039

Evaluating the efficacy of a combination therapy.

S M Snapinn1.   

Abstract

Standard multiple comparison techniques do not adequately address the situation in which one must demonstrate a combination therapy's superiority to both of its components. This paper proposes several alternative tests to deal with this situation, and evaluates the tests with a Monte Carlo sampling experiment that compares the actual with the nominal significance levels of the tests. Data from a clinical trial that compares the efficacy of a combination analgesic/muscle relaxant to its components and placebo in the treatment of low back pain and spasm illustrate the tests.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2961039     DOI: 10.1002/sim.4780060603

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  5 in total

1.  Generalized Confidence Intervals Compatible with the Min Test for Simultaneous Comparisons of One Subpopulation to Several Other Subpopulations.

Authors:  Julia N Soulakova
Journal:  Commun Stat Theory Methods       Date:  2017-06-07       Impact factor: 0.893

2.  Assessing interactions for fixed-dose drug combinations in tumor xenograft studies.

Authors:  Jianrong Wu; Lorraine Tracey; Andrew M Davidoff
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

3.  Effects of Eperisone Hydrochloride and Non-Steroid Anti-Inflammatory Drugs (NSAIDs) for Acute Non-Specific Back Pain with Muscle Spasm: A Prospective, Open-Label Study.

Authors:  Rizaldy Taslim Pinzon; Vincent Ongko Wijaya; Dessy Paramitha; Raymondus Rangga Bagaskara
Journal:  Drug Healthc Patient Saf       Date:  2020-11-16

4.  Assessing interactions for fixed-dose drug combinations in subcutaneous tumor xenograft studies.

Authors:  Jianrong Wu
Journal:  Pharm Stat       Date:  2013-03-07       Impact factor: 1.894

5.  Testing multiple dose combinations in clinical trials.

Authors:  Saswati Saha; Werner Brannath; Björn Bornkamp
Journal:  Stat Methods Med Res       Date:  2019-09-24       Impact factor: 3.021

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.